BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 36539745)

  • 1. Concurrent definitive chemoradiation incorporating intensity-modulated radiotherapy followed by adjuvant chemotherapy in high risk locally advanced cervical squamous cancer: a phase II study.
    Zhang GY; Zhang R; Bai P; Li SM; Zhang YY; Chen YR; Huang MN; Wu LY
    BMC Cancer; 2022 Dec; 22(1):1331. PubMed ID: 36539745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
    Kong L; Zhang YW; Hu CS; Guo Y
    Chin J Cancer; 2010 May; 29(5):551-5. PubMed ID: 20426907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of concurrent weekly carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy as an adjuvant treatment for early-stage cervical cancer patients with positive pelvic lymph nodes.
    Mabuchi S; Takahashi R; Isohashi F; Yokoi T; Ito K; Tsutui T; Ogata T; Yoshioka Y; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Sep; 23(7):1279-86. PubMed ID: 23835505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-field radiotherapy and high-dose-rate brachytherapy with concurrent and adjuvant cisplatin-based chemotherapy for locally advanced cervical cancer: a phase I/II study.
    Chung YL; Jian JJ; Cheng SH; Hsieh CI; Tan TD; Chang HJ; Hung CF; Horng CF; Soong T; Tsou MH
    Gynecol Oncol; 2005 Apr; 97(1):126-35. PubMed ID: 15790448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
    Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
    Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent chemoradiotherapy with paclitaxel and nedaplatin followed by consolidation chemotherapy in locally advanced squamous cell carcinoma of the uterine cervix: preliminary results of a phase II study.
    Zhang MQ; Liu SP; Wang XE
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):821-7. PubMed ID: 20207507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study.
    Strauss HG; Kuhnt T; Laban C; Puschmann D; Pigorsch S; Dunst J; Koelbl H; Haensgen G
    Strahlenther Onkol; 2002 Jul; 178(7):378-85. PubMed ID: 12163992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer.
    Cihoric N; Tsikkinis A; Tapia C; Aebersold DM; Zlobec I; Lössl K
    Radiat Oncol; 2015 Nov; 10():240. PubMed ID: 26597282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.
    Mileshkin LR; Moore KN; Barnes EH; Gebski V; Narayan K; King MT; Bradshaw N; Lee YC; Diamante K; Fyles AW; Small W; Gaffney DK; Khaw P; Brooks S; Thompson JS; Huh WK; Mathews CA; Buck M; Suder A; Lad TE; Barani IJ; Holschneider CH; Van Dyk S; Quinn M; Rischin D; Monk BJ; Stockler MR
    Lancet Oncol; 2023 May; 24(5):468-482. PubMed ID: 37080223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.
    Lee J; Lin JB; Sun FJ; Chen YJ; Chang CL; Jan YT; Wu MH
    Medicine (Baltimore); 2017 Mar; 96(10):e6158. PubMed ID: 28272204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of weekly paclitaxel, weekly carboplatin, and concurrent radiotherapy for primary cervical cancer.
    Rao GG; Rogers P; Drake RD; Nguyen P; Coleman RL
    Gynecol Oncol; 2005 Jan; 96(1):168-72. PubMed ID: 15589596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter prospective phase III clinical randomized study of simultaneous integrated boost intensity-modulated radiotherapy with or without concurrent chemotherapy in patients with esophageal cancer: 3JECROG P-02 study protocol.
    Gao LR; Wang X; Han W; Deng W; Li C; Wang X; Zhao Y; Ni W; Chang X; Zhou Z; Deng L; Wang W; Liu W; Liang J; Zhang T; Bi N; Wang J; Zhai Y; Feng Q; Lv J; Li L; Xiao Z
    BMC Cancer; 2020 Sep; 20(1):901. PubMed ID: 32962674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
    Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
    Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy.
    Lazzari R; Riva G; Augugliaro M; Vavassori A; Dicuonzo S; Cattani F; Comi S; Colombo N; Jereczek-Fossa BA
    Int J Gynecol Cancer; 2020 May; 30(5):607-612. PubMed ID: 32188626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.
    Li J; Liu H; Li Y; Li J; Shen L; Long W; Yang C; Xu H; Xi W; Cai R; Feng W
    Trials; 2022 Jan; 23(1):29. PubMed ID: 35012634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus: mature results of a phase I/II trial.
    Pöttgen C; Gkika E; Stahl M; Abu Jawad J; Gauler T; Kasper S; Trarbach T; Herrmann K; Lehmann N; Jöckel KH; Lax H; Stuschke M
    Radiat Oncol; 2021 Mar; 16(1):59. PubMed ID: 33757534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation.
    Dueñas-Gonzalez A; López-Graniel C; González-Enciso A; Cetina L; Rivera L; Mariscal I; Montalvo G; Gómez E; de la Garza J; Chanona G; Mohar A
    Ann Oncol; 2003 Aug; 14(8):1278-84. PubMed ID: 12881393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of less than 7 weeks of concomitant cisplatin-paclitaxel chemoradiation in locally advanced cervical cancer.
    Martínez-Monge R; Gaztañaga M; Aramendía JM; Cambeiro M; Arbea L; Espinós J; Aristu JJ; Jurado M
    Int J Gynecol Cancer; 2010 Jan; 20(1):133-40. PubMed ID: 20130514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors.
    Shu P; Shen Y; Zhao Y; Xu F; Qiu M; Li Q; Gou H; Cao D; Yang Y; Liu J; Yi C; Liao Z; Luo D; Bi F; Wang X; Li Z
    Med Oncol; 2015 Nov; 32(11):247. PubMed ID: 26433959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.